L’anticorps anti-OC126 (Abagovomab Biosimilar) Monoclonal Human est utilisé pour la détection de OC126 (Abagovomab Biosimilar) dans des échantillons de Souris. Il a été validé pour ELISA et WB.
Research Grade
Reactivité: Humain
Hôte: Souris
Monoclonal
unconjugated
Recombinant Antibody
Restrictions
For Research Use only
Buffer
PBS buffer PH7.5
Stock
-80 °C
Stockage commentaire
store at -80°C
Antigène
OC126 (Abagovomab Biosimilar)
Classe de substances
Biosimilar
Sujet
Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). Abagovomab has been developed by the pharmaceutical company Menarini for the treatment of ovarian cancer. It (ab2) shows high affinity for the paratope of ab1, and binding of ab2 to Ab1 is almost completely inhibited (93%) by the nominal antigen. The administration of F(ab')2 fragments of abagovomab to rats produces anti-CA-125 immunity with the production of IgG and IgM anti-anti-idiotypic antibodies (ab3) that bind both to abagovomab and CA-125. Non-MHC restricted cell-mediated cytotoxicity for NIH OVCAR3 cell lines is also demonstrated.